Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

VRAS (Velys Robot-Assisted Solution) Operational Excellence Study

NCT06563843 · tracked via the Priya Life Science UK tracker
Sponsor
DEO NV
Phase
Observational
Started
2025-01-30
Last updated
2026-10-23

Condition(s) studied

Total Knee Arthroplasty (TKA)

Investigational drug(s) / intervention(s)

Robotic-assisted TKAConventional TKA

Robotic-assisted TKA: Robotic-assisted Total Knee Arthroplasty or total knee replacement is a surgical procedure using a robot to resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.

Conventional TKA: Conventional Total Knee Arthroplasty or total knee replacement is a surgical procedure to manually resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.

Study summary

The aim of this study is to investigate the differences in process set-up, efficiency, OR team workload, instrument trays and OR financial performance when using the VRAS (Velys Robotic Assisted Solution) of DePuy Synthes compared to conventional TKA.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Orthopaedic surgeons performing conventional and robot-assisted TKA Exclusion Criteria: * /

Primary outcome measure(s)

  • Operational efficiency — 3 months
    Efficiency will be assessed using OR time, by comparing the OR days and procedures where TKR is performed conventionally or by using VRAS surgery. A granular analysis from the timestamps will be conducted using standard descriptive statistics. Additionally, the impaction process will be further analyzed, broken down into parts.

Trial sites (10)

FacilityCityRegionStatus
Herz-Jesu Krankenhaus Vienna Austria
Orthopädisches Spital Speising Vienna Austria
AZ Sint-Jan Brugge Bruges Belgium
Hôpital de la Croix Saint-Simon Paris France
Kliniken Hochfranken Münchberg Germany
Clinica Nuova Itor Roma Italy
Hospital General Universitario Gregorio Marañón Madrid Spain
Schulthess Klinik Zurich Switzerland
Leeds Teaching Hospitals NHS Trust Leeds United Kingdom
Liverpool University Hospitals NHS Foundation Trust - Broadgreen Hospital Liverpool United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06563843 on ClinicalTrials.gov ↗ ← All trials in the UK